MedPath

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Not Applicable
Suspended
Conditions
DVT
Anti-coagulation Therapy
Atrial Fibrillation
Joint Surgery Multiple
Pulmonary Embolism
Prosthetic Replacement of Mitral Valve
Interventions
Device: Warfarin GenoSTAT Test
Registration Number
NCT01305148
Lead Sponsor
Iverson Genetic Diagnostics, Inc.
Brief Summary

The WARFARIN Study is a clinical trial designed to determine if the use of genetic information related to warfarin sensitivity can help create a dose of warfarin that will result in less hospitalizations and deaths related to warfarin.

Detailed Description

Not available

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
3800
Inclusion Criteria
  1. Men and women at least 65 years old
  2. Beginning warfarin (0 - 3 doses of warfarin taken at the time of enrollment) for a variety of diseases or conditions that require at least 30 days oral anticoagulation with target INR ≥ 2.0
Exclusion Criteria
  1. Unable to complete the study materials (questionnaires) with or without assistance (for example, those with dementia)
  2. A previous genetically determined warfarin dose
  3. The treating physician does not agree to use the recommended warfarin dose or feels that the patient should not be enrolled in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
RegistryWarfarin GenoSTAT TestSubjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
Randomized - GeneticWarfarin GenoSTAT TestSubjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
Primary Outcome Measures
NameTimeMethod
Incidence of warfarin related clinical events30 days

To determine if using warfarin-related pharmacogenetic information in calculating warfarin doses will change the incidence of warfarin-related clinical events, including major hemorrhage and thromboembolic events, at 30 days after initial dose, when compared to warfarin doses calculated without pharmacogenetic data.

Secondary Outcome Measures
NameTimeMethod
Minor hemorrhagic events90 days

The number of minor hemorrhagic adverse events at 30, 60 and at 90 days separately after warfarin initiation

Prescriber adherence30 days

Prescriber adherence to dosing recommendations through subject interview and comparison of dose recommendation to dose prescribed for the first four doses of warfarin

Warfarin Doses90 days

Comparison of the cumulative warfarin dose necessary to reach warfarin dose stabilization (i.e. two consecutive INR tests within the target range)

Hemorrhagic Events90 days

The number of major hemorrhagic adverse events at 60 and at 90 days separately after warfarin initiation

INR tests30 days

The percentage of the total INR tests performed in the first 30 days which are out of target range

SF-1290 days

The overall, Physical Composite Score (PCS) and Mental Composite Score (MCS) of the SF-12 quality of life questionnaire at 30 days and at 90 days separately after warfarin initiation

INR Tests30 days

Comparison of the number of INR tests performed before warfarin dose stabilization (i.e. two consecutive INR tests within the target range)

Major thromboembolic events90 days

The number of major thromboembolic adverse events at 60 and at 90 days separately after warfarin initiation for

Trial Locations

Locations (56)

St. Alphonsus Regional Medical Center

🇺🇸

Boise, Idaho, United States

Billings Clinic

🇺🇸

Billings, Montana, United States

Medical Consultants, PC

🇺🇸

Muncie, Indiana, United States

Infinity-Northshore

🇺🇸

Fort Lauderdale, Florida, United States

Carle Foundation

🇺🇸

Urbana, Illinois, United States

Orthoarkansas

🇺🇸

Little Rock, Arkansas, United States

Rockford Cardiovascular Research Foundation

🇺🇸

Rockford, Illinois, United States

Cardiology of Atlanta

🇺🇸

Atlanta, Georgia, United States

Atlanta Heart Group

🇺🇸

Decatur, Georgia, United States

Thoracic and Cardiovascular Institute

🇺🇸

Lansing, Michigan, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

Cardiovascular Consultants - Thunderbird

🇺🇸

Glendale, Arizona, United States

St. Mary's

🇺🇸

Evansville, Indiana, United States

Hackensack Medical Center

🇺🇸

Hackensack, New Jersey, United States

Mission Hospital

🇺🇸

Asheville, North Carolina, United States

Aultman Hospital

🇺🇸

Canton, Ohio, United States

NECCR

🇺🇸

Falls River, Massachusetts, United States

Central Bucks Cardiology

🇺🇸

Doylestown, Pennsylvania, United States

Grady Hospital

🇺🇸

Atlanta, Georgia, United States

Palmetto Health Richland

🇺🇸

Columbia, South Carolina, United States

Nebraska Heart

🇺🇸

Lincoln, Nebraska, United States

New Mexico Heart Institute

🇺🇸

Albuquerque, New Mexico, United States

Sanford Health Research

🇺🇸

Fargo, North Dakota, United States

Carolina Cardiology

🇺🇸

Rock Hill, South Carolina, United States

Polyclinic

🇺🇸

Seattle, Washington, United States

Providence Health Network

🇺🇸

Waco, Texas, United States

Corvallis Clinic

🇺🇸

Corvallis, Oregon, United States

Marshfield Clinic Research Foundation

🇺🇸

Marshfield, Wisconsin, United States

Legacy Heart Center

🇺🇸

Plano, Texas, United States

Overlake Hospital

🇺🇸

Bellevue, Washington, United States

Franciscan Research Center

🇺🇸

Tacoma, Washington, United States

The Christ Hospital

🇺🇸

Cincinnati, Ohio, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Veterans' Affairs Medical Center

🇺🇸

Birmingham, Alabama, United States

Colorado Heart & Vascular

🇺🇸

Denver, Colorado, United States

St. Thomas Research Institute

🇺🇸

Nashville, Tennessee, United States

Nexxus Research

🇺🇸

Bedford, Texas, United States

Sarasota Memorial Hospital

🇺🇸

Sarasota, Florida, United States

Cardiovascular Consultants - Phoenix

🇺🇸

Phoenix, Arizona, United States

Comprehensive Cardiovascular Specialists

🇺🇸

Alhambra, California, United States

Okaloosa Heart & Vascular

🇺🇸

Crestview, Florida, United States

Southern Heart Research Institute

🇺🇸

Riverdale, Georgia, United States

Nebraska Heart Institute

🇺🇸

Grand Island, Nebraska, United States

Alegent

🇺🇸

Omaha, Nebraska, United States

Intermountain Medical Center

🇺🇸

Murray, Utah, United States

Family Health Care of Ellensburg

🇺🇸

Ellensburg, Washington, United States

Swedish Hospital

🇺🇸

Seattle, Washington, United States

St. Joseph's Medical Center

🇺🇸

Stockton, California, United States

Infinity Clinical Research

🇺🇸

Hollywood, Florida, United States

Heart Rhythm Specialists

🇺🇸

Naples, Florida, United States

Community Hospital Anderson

🇺🇸

Anderson, Indiana, United States

Cox Medical Center

🇺🇸

Springfield, Missouri, United States

Bend Memorial Clinic

🇺🇸

Bend, Oregon, United States

Scott & White

🇺🇸

Temple, Texas, United States

Kansas City Heart Foundation

🇺🇸

Kansas City, Missouri, United States

Texas Cardiac Arrhythmia

🇺🇸

Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath